PepGen’s ambition is to harness the power of peptide conjugation technologies in order to address the delivery challenges associated with nucleic acid therapeutics and thus realise the clinical potential of these transformative therapeutics. The company’s newly formed Scientific Advisory Board will bring cutting-edge neuromuscular disease and oligonucleotide delivery expertise as it advances its enhanced delivery oligonucleotide (EDO) therapeutics towards the clinic.
Professor Matthew Wood, M.D., PhD, one of PepGen's founders, will lead the company's board as Chairman. Professor Wood, who is also Chair of the BioEscalator Management Board, is Professor of Neuroscience in the Department of Paediatrics, Deputy Head of Division (Innovation), and Deputy to the Pro-Vice-Chancellor for Innovation at the University of Oxford. He is also the Director of the Oxford Neuromuscular Centre and the Oxford Centre for Rare Disease. He has a distinguished international profile, and over the last decade has catalysed major advances in the development of oligonucleotide therapies for several neuromuscular disorders.
Professor Wood will be joined by:
- Art Krieg, M.D., the Founder and Chief Scientific Officer (CSO) at Checkmate Pharmaceuticals
- Elizabeth McNally, M.D., PhD, a human geneticist and cardiologist with experience in neuromuscular disorders
- Charles Thornton, M.D., the Saunders Family Distinguished Professor in Neuromuscular Research in the Department of Neurology, the Centre for RNA Biology, and the Department of Neuroscience at the University of Rochester Medical Centre
- Jonathon Watts, PhD, an Associate Professor at the RNA Therapeutics Institute, part of the University of Massachusetts Medical School
- Brenda Wong, M.D., the Director of the Duchenne Muscular Dystrophy Centre at the University of Massachusetts Medical Centre and Professor of Paediatrics and Neurology at the University of Massachusetts Medical School.
PepGen was the first company to take up residence in the BioEscalator in the newly constructed Innovation Building in 2018, a facility created to support high-growth biotech start-ups and increase the commercialisation of innovative technologies that were being developed at Oxford. The company focuses on novel methods of drug delivery, using peptide technology to increase the bioavailability of therapeutics across a variety of indications. The company was founded in 2018 with an initial seed investment from OSI. PepGen raised a $45 million Series A in December 2020 with RA Capital Management as the lead investor; Oxford Sciences Innovation (OSI), CureDuchenne Ventures and the University of Oxford also participated in the round. For more information, visit https://www.pepgen.com/.